StockNews.AI
MDXG
StockNews.AI
35 days

MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026

1. CMS proposes fixed reimbursement for skin substitutes at $125.38 per cm². 2. 2024 Medicare spend on skin substitutes reached nearly $10 billion. 3. Reimbursement reform aims to lower fraud, waste, and abuse in the market. 4. MDXG is positioned to thrive under new reimbursement models and regulations. 5. Upcoming comment period for CMS ends September 13, 2025.

5m saved
Insight
Article

FAQ

Why Bullish?

The proposed pricing structure could stabilize MDXG revenues, benefiting long-term growth. Historical price adjustments in healthcare reimbursement often lead to revenue increases for compliant companies.

How important is it?

The reform directly impacts MDXG's core business, potentially enhancing its market position. A strong reimbursement framework is critical for healthcare providers, influencing stock prices significantly.

Why Long Term?

Changes will be implemented on January 1, 2026, aligning MDXG’s product strategies accordingly. Past examples show companies adapting successfully to reimbursement reforms over 1-3 years.

Related Companies

HNRGSYNHAHLVRTU
New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse July 15, 2025 09:15 ET  | Source: MiMedx Group, Inc MARIETTA, Ga., July 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) proposal. “We welcome and support improvements to Medicare’s reimbursement of skin substitutes across all care settings. The proposed rule, which was published yesterday afternoon, calls for a move away from the ASP methodology in favor of a fixed price per square centimeter of $125.38 for all skin substitutes. While many may take issue with the proposed price, reform in this category is long overdue,” stated Joseph H. Capper, MIMEDX Chief Executive Officer. Mr. Capper continued, “The skin substitute market has experienced a proliferation of unsavory business practices over the last several years, as referenced in several recently announced enforcement actions. Under the current reimbursement methodology, the 2024 Medicare spend for skin substitutes in the private office and associated care settings had ballooned to nearly $10 billion, up from approximately $1.5 billion in 2022. Reimbursement reform that restores rational market behavior and diminishes fraud, waste and abuse will serve to benefit stakeholders, taxpayers and, most importantly, patients. We look forward to providing our perspective and recommendations to CMS during the upcoming comment period, which concludes on September 13, 2025. As always, we remain focused on supporting our customers and their patients as they navigate this evolving landscape.”   “Importantly, MIMEDX is well-positioned to excel in an environment in which product capabilities, supported by robust clinical evidence, determine selection and usage. The recently announced Wasteful and Inappropriate Service Reduction (“WISeR”) model, the pending Local Coverage Determinations (“LCDs”), and now the PFS rules are all set for implementation on January 1, 2026. We plan to discuss this topic in more detail on our upcoming second quarter earnings call,” concluded Mr. Capper. The CY 2026 Hospital Outpatient Prospective Payment System (“OPPS”), while mentioned extensively in the PFS, has not yet been published but is also expected to be released in proposed form and slated for implementation on January 1, 2026. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact:Matt NotarianniInvestor Relations470-304-7291mnotarianni@mimedx.com

Related News